Show simple item record

dc.contributor.authorAnido Herranz, Urbano 
dc.contributor.authorFernández Nuñez, Natalia 
dc.contributor.authorAfonso-Afonso, J.
dc.contributor.authorSantome-Couto, L.
dc.contributor.authorMedina-Colmenero, A.
dc.contributor.authorFernandez-Calvo, O.
dc.contributor.authorLazaro-Quintela, M.
dc.contributor.authorVázquez Estévez, Sergio 
dc.date.accessioned2022-02-02T08:17:29Z
dc.date.available2022-02-02T08:17:29Z
dc.date.issued2019
dc.identifier.issn1699-048X
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/30051212es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16076
dc.description.abstractAdministration of chemotherapy in prostate cancer depends on patient fitness. In unfit patients, physiological impairment determines the optimum treatment. Although no consensus on assessing patient fitness currently exists, this article proposes an algorithm combining the available information for administering chemotherapy, and in particular docetaxel, in unfit patients. It was constructed by reviewing factors that can influence treatment, such as performance status, taxane-related comorbidities and nutritional status. Geriatric scales for prostate cancer patients and alternative treatment regimens for this population are also reviewed. In summary, patients require overall assessment to optimise treatment. Use of docetaxel should be restricted in unfit patients, and other options must be evaluated, because of high toxicity and low efficacy.en
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHumans *
dc.subject.meshKarnofsky Performance Status *
dc.subject.meshProstatic Neoplasms *
dc.subject.meshPhysical Fitness *
dc.subject.meshAged *
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols *
dc.subject.meshAlgorithms *
dc.titleChemotherapy management for unfit patients with metastatic castration-resistant prostate canceren
dc.typeArtigoes
dc.identifier.doi10.1007/s12094-018-1928-y
dc.identifier.pmid30051212
dc.identifier.sophos34974
dc.issue.number3es
dc.journal.titleClinical & Translational Oncologyes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Lugo, Cervo e Monforte de lemos - Complexo Hospitalario Universitario Lucus Augusti::Oncoloxía médicaes
dc.relation.publisherversionhttps://link.springer.com/content/pdf/10.1007/s12094-018-1928-y.pdfes
dc.rights.accessRightsopenAccesses
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada *
dc.subject.decsanciano *
dc.subject.decsneoplasias de la próstata *
dc.subject.decsalgoritmos *
dc.subject.decsaptitud física *
dc.subject.decsgrado de actividad de Karnofsky *
dc.subject.decshumanos *
dc.subject.keywordCHUSes
dc.subject.keywordHULAes
dc.typefidesArtículo de Revisiónes
dc.typesophosArtículo de Revisiónes
dc.volume.number21es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional